TORONTO (PRWEB) January 10, 2019
In this webinar, challenges of rare diseases studies focusing on gene therapy treatments, including appropriate study design, statistical analyses and long-term post-authorisation pharmacovigilance and risk management requirements will be examined. Use of appropriate data capture and data quality oversight methods will also be discussed.
Join Karen Ooms, Executive Vice President and Head of Statistics at Quanticate, David Hukin, Managing Director at QVigilance, and Claude Price, Associate Director of Clinical Data Management at Quanticate for a live webinar on Tuesday, January 29, 2019 at 11am EST (4pm GMT) to learn about:
- Appropriate study design and statistical analyses
- Long-term post-authorisation pharmacovigilance
- Risk management activities
- Appropriate data capture methodologies
- Key considerations for improving data quality (Data Quality Oversight techniques)
For more information or to register for this event, visit Gene Therapy for Rare Diseases: Considerations for Both Clinical and Post-Marketing Studies
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.